I
Ibrahim Tekedereli
Researcher at University of Texas MD Anderson Cancer Center
Publications - 15
Citations - 1537
Ibrahim Tekedereli is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Autophagy & Doxorubicin. The author has an hindex of 10, co-authored 14 publications receiving 1329 citations. Previous affiliations of Ibrahim Tekedereli include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Paraneoplastic Thrombocytosis in Ovarian Cancer
Rebecca L. Stone,Alpa M. Nick,Iain A. McNeish,Frances R. Balkwill,Hee Dong Han,Justin Bottsford-Miller,Rajesha Rupaimoole,Guillermo N. Armaiz-Pena,Chad V. Pecot,Jermaine Coward,Michael T. Deavers,Hernan G. Vasquez,Diana L. Urbauer,Charles N. Landen,Wei Hu,Hannah Gershenson,Koji Matsuo,Mian M.K. Shahzad,Erin R. King,Ibrahim Tekedereli,Bulent Ozpolat,Edward H. Ahn,Virginia K. Bond,Rui Wang,Angela F. Drew,Francisca C. Gushiken,Donald M. Lamkin,Katherine Collins,Koen DeGeest,Susan K. Lutgendorf,Wah Chiu,Gabriel Lopez-Berestein,Vahid Afshar-Kharghan,Anil K. Sood +33 more
TL;DR: Findings support the existence of a paracrine circuit wherein increased production of thrombopoietic cytokines in tumor and host tissue leads to paraneoplasticThrombocytosis, which fuels tumor growth.
Journal ArticleDOI
Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer.
TL;DR: The data suggest that, depending on the cellular features, either the induction or the inhibition of autophagy can provide therapeutic benefits to patients and that the design and synthesis of the first-generation modulators of Autophagy may provide the tools for proof of concept experiments and the impetus for translational studies that may ultimately lead to new therapeutic strategies in cancer.
Journal ArticleDOI
Targeted Silencing of Elongation Factor 2 Kinase Suppresses Growth and Sensitizes Tumors to Doxorubicin in an Orthotopic Model of Breast Cancer
Ibrahim Tekedereli,S. Neslihan Alpay,Clint D.J. Tavares,Zehra E. Cobanoglu,Tamer S. Kaoud,Ibrahim Halil Sahin,Anil K. Sood,Gabriel Lopez-Berestein,Kevin N. Dalby,Bulent Ozpolat +9 more
TL;DR: The notion that the disruption of eEF-2K expression in breast cancer cells results in the down-regulation of signaling pathways affecting growth, survival and resistance and has potential as a therapeutic approach for the treatment of breast cancer is supported.
Journal ArticleDOI
Therapeutic silencing of Bcl-2 by systemically administered siRNA nanotherapeutics inhibits tumor growth by autophagy and apoptosis and enhances the efficacy of chemotherapy in orthotopic xenograft models of ER (-) and ER (+) breast cancer
Ibrahim Tekedereli,S. Neslihan Alpay,Ugur Akar,Erkan Yuca,Cristian Ayugo-Rodriguez,He Dong Han,Anil K. Sood,Gabriel Lopez-Berestein,Bulent Ozpolat +8 more
TL;DR: The data provide the first evidence that in vivo therapeutic targeting Bcl-2 by systemically administered nanoliposomal-siRNA significantly inhibits growth of both ER(−) and ER(+) breast tumors and enhances the efficacy of chemotherapy, suggesting that therapeutic silencing of Bcl -2 by siRNA is a viable approach in breast cancers.
Journal ArticleDOI
Molecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer
Yang Jin,Su Qu,Martina Tesikova,Ling Wang,Alexandr Kristian,Gunhild Mari Mælandsmo,Haiying Kong,Tianzhou Zhang,Carmen Jerónimo,Manuel R. Teixeira,Erkan Yuca,Ibrahim Tekedereli,Kivanc Gorgulu,Neslihan Alpay,Anil K. Sood,Gabriel Lopez-Berestein,Håvard E. Danielsen,Bulent Ozpolat,Fahri Saatcioglu,Fahri Saatcioglu +19 more
TL;DR: It is shown that proteins encoded by two androgen-regulated genes, kallikrein related peptidase 4 (KLK4) and promyelocytic leukemia zinc finger (PLZF), integrate optimal functioning of AR and mTOR signaling in PCa cells, which may be a viable target for therapy.